Jeremy Bender - 08 Jul 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
08 Jul 2022
Transactions value $
$-35,900
Form type
4
Filing time
12 Jul 2022, 19:30:18 UTC
Previous filing
06 Jul 2022
Next filing
20 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale $-35,900 -1,795 -0.14% $20.00 1,261,292 08 Jul 2022 Direct F1
holding DAWN Common Stock 281,574 08 Jul 2022 See Footnote F2
holding DAWN Common Stock 281,574 08 Jul 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person September 15, 2021.
F2 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F3 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.